811 F.3d 1345
Fed. Cir.2016Background
- Purdue (with Rhodes) developed a reformulated OxyContin® API with very low levels (<25 ppm) of the impurity 14‑hydroxy (an ABUK) by adding a second hydrogenation step after forming oxycodone hydrochloride; they discovered that an isomer 8α converts to 14‑hydroxy during acid salting.
- Purdue/Rhodes obtained three “low‑ABUK” patents (’799, ’800, ’072) covering the low‑impurity product and Grunenthal owned the ’383 patent covering a thermoformed, PEO‑based abuse‑deterrent tablet (Reformulated OxyContin®). Purdue licensed Grunenthal’s tech and received FDA approval for Reformulated OxyContin®.
- Teva filed ANDAs to market generic Reformulated OxyContin®; Purdue (and Grunenthal) sued Teva for infringement. The district court tried the Teva case, found infringement but held all asserted claims invalid (anticipated or obvious), and dismissed related suits against Epic, Mylan, and Amneal on collateral estoppel grounds.
- The Federal Circuit reviews anticipation (fact, clear error) and obviousness (legal conclusion reviewed de novo; underlying facts for clear error) and considered prior art such as Chiu and McGinity in assessing invalidity.
- The district court held the low‑ABUK product claims obvious because hydrogenation to remove 14‑hydroxy was known and the claimed product does not differ structurally/functionally based on whether 14‑hydroxy derived from 8α or 8β; it held the ’383 patent claims anticipated by McGinity (hot‑melt extrusion of high‑MW PEO inherently yields >500 N breaking strength).
Issues
| Issue | Plaintiff's Argument (Purdue/Grunenthal) | Defendant's Argument (Teva/Intervenors) | Held |
|---|---|---|---|
| Whether low‑ABUK product claims are nonobvious because discovery of 8α was the inventive core | Discovery of 8α as the source of residual 14‑hydroxy makes the invention nonobvious (analogy to Eibel) | Even if 8α discovery was new, the claimed product is the low‑ABUK API; hydrogenation to remove 14‑hydroxy was known and the source (8α vs 8β) does not change product structure or removal | Claims obvious; identification of 8α did not render product nonobvious |
| Whether the claim limitation “at least a portion of the 14‑hydroxy is derived from 8α” avoids obviousness | Limitation distinguishes claim from prior art and was added after Chapman decision to avoid obviousness | That language is a process‑based limitation (product‑by‑process) that does not impart structural/functional difference to the product; thus immaterial to product obviousness | Limitation treated as a process limitation and disregarded for obviousness; not sufficient to avoid invalidity |
| Whether secondary considerations support nonobviousness (commercial success, long‑felt need, praise/failure of others) | Commercial success of Rhodes/Purdue and praise/recognition from competitors show nexus and nonobviousness | Sales driven by corporate structure (affiliate supply), lack of evidence of others’ failed attempts, and timing tied to FDA mandate undercut nexus and other secondary factors | District court did not clearly err; secondary considerations do not overcome obviousness finding |
| Whether ’383 patent claims (PEO thermoformed, ≥60% PEO, breaking strength ≥500 N, opioid with abuse potential in controlled‑release matrix) are anticipated by McGinity | McGinity does not disclose opioids specifically, nor inherently a ≥500 N breaking strength; reliance on combined disclosures improperly picks and chooses | McGinity discloses hot‑melt extrusion of high‑MW PEO for controlled‑release analgesics broadly; experimental recreations (Muzzio) showed tablets per McGinity withstand >500 N; opioid class is encompassed | District court properly found McGinity discloses each limitation inherently; anticipation affirmed |
| Whether collateral estoppel barred Purdue’s suits against Epic, Mylan, Amneal after Teva judgment | Purdue argued for separate adjudication | Purdue conceded collateral estoppel applied below and did not rebut on appeal | Dismissals affirmed; collateral estoppel precluded relitigation |
Key Cases Cited
- Schering Corp. v. Geneva Pharm., 339 F.3d 1373 (Fed. Cir.) (anticipation requires a single prior art reference disclosing every claim limitation)
- Atlas Powder Co. v. Ireco, Inc., 190 F.3d 1342 (Fed. Cir.) (anticipation reviewed for clear error)
- Graham v. John Deere Co., 383 U.S. 1 (Graham factual framework for obviousness)
- KSR Int’l Co. v. Teleflex, 550 U.S. 398 (obviousness legal standard and framework)
- Eibel Process Co. v. Minnesota & Ontario Paper Co., 261 U.S. 45 (Sup. Ct.) (inventor’s discovery of a nonobvious problem can support nonobviousness of solution)
- Amgen Inc. v. F. Hoffmann‑LaRoche Ltd., 580 F.3d 1340 (Fed. Cir.) (product‑by‑process claims: focus on product; process relevant only if it imparts structural/functional difference)
- Greenliant Sys., Inc. v. Xicor LLC, 692 F.3d 1261 (Fed. Cir.) (same principle on product‑by‑process claims)
- Pharmacia & Upjohn Co. v. Mylan Pharm., Inc., 170 F.3d 1373 (Fed. Cir.) (collateral estoppel application on appeal limited to reviewing district court’s application)